143 related articles for article (PubMed ID: 35158466)
1. Lymphopenia during treatment with dimethyl fumarate in patients with multiple sclerosis: Prevalence, predicting factors and clinical outcomes.
Dinoto A; Sartori A; Cheli M; Pasquin F; Baldini S; Bratina A; Bosco A; Manganotti P
Mult Scler Relat Disord; 2022 Jan; 57():103357. PubMed ID: 35158466
[TBL] [Abstract][Full Text] [Related]
2. Relationship between lymphopenia and disease activity in persons with multiple sclerosis treated with dimethyl fumarate.
Chu L; Balusha A; Casserly C; Berger W; Morrow SA
Mult Scler Relat Disord; 2022 Jan; 57():103384. PubMed ID: 35158477
[TBL] [Abstract][Full Text] [Related]
3. Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis.
Lucchini M; Prosperini L; Buscarinu MC; Centonze D; Conte A; Cortese A; Elia G; Fantozzi R; Ferraro E; Gasperini C; Ianniello A; Landi D; Marfia GA; Nociti V; Pozzilli C; Salvetti M; Tortorella C; Mirabella M
J Neurol; 2021 Jun; 268(6):2238-2245. PubMed ID: 33496861
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for development of lymphopenia in dimethyl fumarate-treated patients with multiple sclerosis.
Ravn J; Jensen HB; Kant M; Andersen PB; Góra MK; Sejbaek T
Mult Scler Relat Disord; 2022 Nov; 67():104081. PubMed ID: 35944466
[TBL] [Abstract][Full Text] [Related]
5. Lower lymphocyte counts and older age are associated with reduced multiple sclerosis disease activity during dimethyl fumarate treatment.
Garbo R; Lorenzut S; Del Negro I; Merlino G; Gigli GL; Cargnelutti D; Valente M
Mult Scler Relat Disord; 2021 Apr; 49():102781. PubMed ID: 33524927
[TBL] [Abstract][Full Text] [Related]
6. Simple parameters from complete blood count predict lymphopenia, adverse effects and efficacy in people with MS treated with dimethyl fumarate.
Baeva ME; Metz LM; Greenfield J; Camara-Lemarroy CR
Mult Scler Relat Disord; 2023 Jun; 74():104699. PubMed ID: 37031552
[TBL] [Abstract][Full Text] [Related]
7. Fingolimod and Dimethyl-Fumarate-Derived Lymphopenia is not Associated with Short-Term Treatment Response and Risk of Infections in a Real-Life MS Population.
Boffa G; Bruschi N; Cellerino M; Lapucci C; Novi G; Sbragia E; Capello E; Uccelli A; Inglese M
CNS Drugs; 2020 Apr; 34(4):425-432. PubMed ID: 32193826
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for lymphopenia in patients with relapsing-remitting multiple sclerosis treated with dimethyl fumarate.
Morales FS; Koralnik IJ; Gautam S; Samaan S; Sloane JA
J Neurol; 2020 Jan; 267(1):125-131. PubMed ID: 31583427
[TBL] [Abstract][Full Text] [Related]
9. Bariatric surgery and dimethyl fumarate-induced lymphopenia in patients with multiple sclerosis.
Andreozzi V; Capuano R; Scannapieco S; Barra F; d'Arco B; Giordano C; Caterino M; De Marca U; Di Filippo F; Di Gregorio M; Barone P
Neurol Sci; 2024 Jun; 45(6):2807-2810. PubMed ID: 38150132
[TBL] [Abstract][Full Text] [Related]
10. Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarate and impact of treatment switch on lymphocyte and leukocyte count.
Baharnoori M; Gonzalez CT; Chua A; Diaz-Cruz C; Healy BC; Stankiewicz J; Weiner HL; Chitnis T
Mult Scler Relat Disord; 2018 Feb; 20():51-57. PubMed ID: 29304497
[TBL] [Abstract][Full Text] [Related]
11. Incidence of persistent lymphopenia in people with multiple sclerosis on dimethyl fumarate.
Wood CH; Robertson NP; Htet ZM; Tallantyre EC
Mult Scler Relat Disord; 2022 Feb; 58():103492. PubMed ID: 35066268
[TBL] [Abstract][Full Text] [Related]
12. Early predictive risk factors for dimethyl fumarate-associated lymphopenia in patients with multiple sclerosis.
Sainz de la Maza S; Sabin Muñoz J; Pilo de la Fuente B; Thuissard I; Andreu-Vázquez C; Galán Sánchez-Seco V; Salgado-Cámara P; Costa-Frossard L; Monreal E; Ayuso-Peralta L; García-Vasco L; García-Domínguez JM; Martínez-Ginés ML; Muñoz Fernández C; Díaz-Díaz J; Oreja-Guevara C; Gómez-Moreno M; Martín H; Rubio-Flores L; Blasco MR; Villar-Guimerans LM; Aladro Y;
Mult Scler Relat Disord; 2022 Mar; 59():103669. PubMed ID: 35150979
[TBL] [Abstract][Full Text] [Related]
13. Dimethyl fumarate-induced lymphocyte count drop is related to clinical effectiveness in relapsing-remitting multiple sclerosis.
Tsantes E; Curti E; Ferraro D; Lugaresi A; Baldi E; Montepietra S; Immovilli P; Simone AM; Mancinelli L; Strumia S; Vitetta F; Foschi M; Ferri C; Ferrarini C; Sola P; Granella F
Eur J Neurol; 2021 Jan; 28(1):269-277. PubMed ID: 32931130
[TBL] [Abstract][Full Text] [Related]
14. Effects of dimethyl fumarate on lymphocyte subsets.
Berkovich R; Weiner LP
Mult Scler Relat Disord; 2015 Jul; 4(4):339-41. PubMed ID: 26195053
[TBL] [Abstract][Full Text] [Related]
15. Delayed and recurrent dimethyl fumarate induced-lymphopenia in patients with multiple sclerosis.
Borrelli S; Mathias A; Goff GL; Pasquier RD; Théaudin M; Pot C
Mult Scler Relat Disord; 2022 Jul; 63():103887. PubMed ID: 35636269
[TBL] [Abstract][Full Text] [Related]
16. Patient-specific factors modulate leukocyte response in dimethyl fumarate treated MS patients.
Goldman MD; Dwyer L; Coleman R; Sohn MW; Stuve O
PLoS One; 2020; 15(2):e0228617. PubMed ID: 32045436
[TBL] [Abstract][Full Text] [Related]
17. Severe multiple sclerosis reactivation during prolonged lymphopenia after dimethyl fumarate discontinuation.
Zecca C; Antozzi CG; Torri Clerici V; Ferrazzini M; Mantegazza RE; Rossi S; Gobbi C
Acta Neurol Scand; 2018 Jun; 137(6):623-625. PubMed ID: 29205270
[TBL] [Abstract][Full Text] [Related]
18. A case of progressive multifocal leukoencephalopathy under dimethyl fumarate treatment without severe lymphopenia or immunosenescence.
Diebold M; Altersberger V; Décard BF; Kappos L; Derfuss T; Lorscheider J
Mult Scler; 2019 Oct; 25(12):1682-1685. PubMed ID: 31208265
[TBL] [Abstract][Full Text] [Related]
19. Persistent severe lymphopenia 5 years after dimethyl fumarate discontinuation.
Caldito NG; O'Leary S; Stuve O
Mult Scler; 2021 Jul; 27(8):1306-1308. PubMed ID: 33620273
[TBL] [Abstract][Full Text] [Related]
20. Factors associated with dimethyl fumarate-induced lymphopenia.
Sainz de la Maza S; Medina S; Villarrubia N; Costa-Frossard L; Monreal E; Tejeda-Velarde A; Rodríguez-Martín E; Roldán E; Álvarez-Cermeño JC; Villar LM
J Neurol Sci; 2019 Mar; 398():4-8. PubMed ID: 30658226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
